US20210085720A1 - Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy - Google Patents

Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy Download PDF

Info

Publication number
US20210085720A1
US20210085720A1 US17/099,140 US202017099140A US2021085720A1 US 20210085720 A1 US20210085720 A1 US 20210085720A1 US 202017099140 A US202017099140 A US 202017099140A US 2021085720 A1 US2021085720 A1 US 2021085720A1
Authority
US
United States
Prior art keywords
tet2
cell
cancer
cells
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/099,140
Other languages
English (en)
Inventor
Barbara Sennino
Kyle Jacoby
Stefanie Mandl-Cashman
Michael M. Dubreuil
John Gagnon
Alex Franzusoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adoc SSF LLC
Original Assignee
Pact Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pact Pharma Inc filed Critical Pact Pharma Inc
Priority to US17/099,140 priority Critical patent/US20210085720A1/en
Publication of US20210085720A1 publication Critical patent/US20210085720A1/en
Assigned to PACT PHARMA, INC. reassignment PACT PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Dubreuil, Michael M., GAGNON, JOHN, FRANZUSOFF, ALEX, JACOBY, Kyle, MANDL-CASHMAN, Stefanie, SENNINO, Barbara
Assigned to ADOC SSF, LLC reassignment ADOC SSF, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PACT PHARMA, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • Tet methylcytosine dioxygenase 2 is a gene that encodes the protein methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine.
  • the encoded protein appears to be involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. However, the exact function of the protein is unknown.
  • the TET2 gene is found on the cytogenetic location 4q24 (the long (q) arm of chromosome 4 at position 24).
  • Other names for the TET2 gene include F1120032, KIAA1546, MGC125715, probably methylcytosine dioxygenase TET2, probably methylcytosine dioxygenase TET2 isoform a, probably methylcytosine dioxygenase TET2 isoform b, tet oncogene family member 2, and TET2_HUMAN.
  • TET2 protein is involved in regulating the process of transcription, which is the first step in protein production. Although this protein is found throughout the body, it may play a particularly important role in the production of blood cells from hematopoietic stem cells. These stem cells are located within the bone marrow and have the potential to develop into red blood cells, white blood cells, and platelets. The TET2 protein appears to act as a tumor suppressor, preventing cells from growing and dividing in an uncontrolled way.
  • somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukemia (CMML), acute myeloid leukemias (AML) and secondary AML (sAML).
  • MDS myelodysplastic syndromes
  • MPN myeloproliferative neoplasms
  • MDS/MPN overlap syndromes including chronic myelomonocytic leukemia (CMML), acute myeloid leukemias (AML) and secondary AML (sAML).
  • TET2 mutations have prognostic value in cytogenetically normal acute myeloid leukemia (CN-AML). “Nonsense” and “frameshift” mutations in this gene are associated with poor outcome on standard therapies in this otherwise favorable-risk patient subset. Loss of function TET2 mutations may also have a possible causal role in atherogenesis.
  • TET2 may also be a candidate for active DNA demethylation, the catalytic removal of the methyl group added to the fifth carbon on the cytosine base
  • TET2 gene mutations are acquired during a person's lifetime and are present only in certain cells. These changes, which are called somatic mutations, are not inherited. Somatic mutations in the TET2 gene have been identified in a small number of people with essential thrombocythemia, which is a condition characterized by high numbers of platelets in the blood. Platelets are the blood cells involved in blood clotting. TET2 gene mutations alter the TET2 protein in different ways; however, all of them appear to result in a nonfunctional protein. The role these mutations play in the development of essential thrombocythemia is unknown.
  • Somatic mutations in the TET2 gene are associated with polycythemia vera, a disorder characterized by uncontrolled blood cell production. These mutations are thought to result in a nonfunctional protein. Mutations in this gene have been found in approximately 16 percent of people with polycythemia vera. It is unclear what role these mutations play in the development of polycythemia vera.
  • Somatic mutations in the TET2 gene are associated with primary myelofibrosis. This condition is characterized by scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. It is unclear what role the TET2 gene mutations play in the development of primary myelofibrosis.
  • Somatic TET2 gene mutations are also associated with certain types of cancer of blood-forming cells (leukemia) and a disease of the blood and bone marrow called myelodysplastic syndrome. These mutations are thought to result in a nonfunctional TET2 protein. A loss of TET2 protein in hematopoietic stem cells may lead to uncontrolled growth and division of these cells.
  • researchers are working to determine exactly what role TET2 gene mutations play in the development of bone marrow disorders.
  • TET2 mutations have also been shown to be associated with myeloid neoplasia.
  • TET2-disruption in CAR T cells have also been shown to be associated with cancer remission in subjects and long-term CAR T cell survival post-infusion (Fraietta et al., 2018, Nature, 558(7709), 307-312). Specifically, TET2-disrupted CART cells modified by viral editing methods were identified in a patient with remission and accounted for nearly all edited cells two (2) months post profusion.
  • Cell therapies designed to express a NeoTCR with a concurrent knockout or knockdown of the TET2 gene have not been previously pursued. Furthermore, there is an unmet need to develop cell therapies that have long persistence times and/or ideally full engraftment as memory stem cells in order to allow for cell therapies to be single or infrequently dosed therapies.
  • therapies that modulate the expression of TET2 on T cells need to be engineered precisely in order to prevent oncogenic phenotypes of such therapies.
  • Such therapies are that include a knockout or knockdown TET2 that is specific to T cells are described herein.
  • the present inventions described herein provide for cells that were engineered to modulate the endogenous expression of the TET2 gene.
  • the presently disclosed subject matter provides a cell, comprising an exogenous T cell receptor (TCR), and a gene disruption of a TET2 locus.
  • the gene disruption comprises a substitution, a deletion, an insertion, or any combination thereof.
  • the gene disruption comprises a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof.
  • the gene disruption of the TET2 locus results in a non-functional TET2 protein.
  • the gene disruption of the TET2 locus results in knockout of the TET2 gene expression.
  • the cell comprises a gRNA and a Cas9 nuclease.
  • the gRNA comprises a nucleotide sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • the gene disruption of the TET2 locus enhances cell persistence. In certain embodiments, the gene disruption of the TET2 locus enhances memory cell differentiation.
  • the cell is a primary cell. In certain embodiments, the cell is a patient-derived cell. In certain embodiments, the cell is a lymphocyte. In certain embodiments, the cell is a T cell. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95-, CCR7+, and CD27+. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95+, CD27+, CCR7+. In certain embodiments, the cell is CD45RO+, CD62L+, CD28+, CD95+, CCR7+, CD27+, CD127+.
  • the exogenous TCR is a patient derived TCR.
  • the exogenous TCR comprises a signal sequence, a first and second 2A sequence, and a TCR polypeptide sequence.
  • the exogenous TCR recognizes a cancer antigen.
  • the cancer antigen is a neoantigen.
  • the cancer antigen is a patient specific antigen.
  • the presently disclosed subject matter provides a cell modified by a process, the process comprising introducing into a cell a homologous recombination (HR) template nucleic acid sequence, recombining the HR template nucleic acid into an endogenous locus of the cell, and disrupting a TET2 locus of the cell.
  • the HR template comprises first and second homology arms homologous to first and second target nucleic acid sequences, and a TCR gene sequence positioned between the first and second homology arms.
  • the HR template comprises a first 2A-coding sequence positioned upstream of the TCR gene sequence and a second 2A-coding sequence positioned downstream of the TCR gene sequence, wherein the first and second 2A-coding sequences code for the same amino acid sequence that are codon-diverged relative to each other.
  • the 2A-coding sequence is a P2A-coding sequence.
  • a sequence coding for the amino acid sequence Gly Ser Gly is positioned immediately upstream of the 2A-coding sequences.
  • the HR template comprises a sequence coding for a Furin cleavage site positioned upstream of the second 2A-coding sequence.
  • the first and second homology arms are each from about 300 bases to about 2,000 bases in length. In certain embodiments, the first and second homology arms are each from about 600 bases to about 2,000 bases in length.
  • the HR template further comprises a signal sequence positioned between the first 2A-coding sequence and the TCR gene sequence. In certain embodiments, the HR template comprises a second TCR sequence positioned between the second 2A-coding sequence and the second homology arm.
  • the HR template comprises a first signal sequence positioned between the first 2A-coding sequence and the first TCR gene sequence, and a second signal sequence positioned between the second 2A-coding sequence and the second TCR gene sequence, wherein the first and the second signal sequences encode for the same amino acid sequence and are codon diverged relative to each other.
  • the signal sequence is a human growth hormone signal sequence.
  • the HR template is non-viral. In certain embodiments, the HR template is a circular DNA. In certain embodiments, the HR template is a linear DNA. In certain embodiments, the introducing occurs via electroporation.
  • the recombining comprises cleavage of the endogenous locus by a nuclease, and recombination of the HR template nucleic acid sequence into the endogenous locus by homology directed repair.
  • the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • the nuclease comprises a gRNA.
  • the disrupting comprises introducing a substitution, a deletion, an insertion, or any combination thereof. In certain embodiments, the disrupting comprises introducing a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof. In certain embodiments, the disrupting results in a non-functional TET2 protein. In certain embodiments, the disrupting results in knockout of the TET2 gene expression.
  • the disrupting comprises cleavage of the TET2 locus by a nuclease.
  • the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • the nuclease comprises a gRNA.
  • the gRNA comprises a sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • the nuclease is expressed by a vector.
  • the gRNA is expressed by a vector.
  • the vector is a viral vector.
  • the vector is a non-viral vector.
  • the disrupting of the TET2 locus enhances cell persistence. In certain embodiments, the disrupting of the TET2 locus enhances memory cell differentiation.
  • the cell is a primary cell. In certain embodiments, the cell is a patient-derived cell. In certain embodiments, the cell is a lymphocyte. In certain embodiments, the cell is a T cell. In certain embodiments, the T cell is a patient-derived cell. In certain embodiments, the cell is a young T cell. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95-, CCR7+, and CD27+. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95+, CD27+, CCR7+. In certain embodiments, the cell is CD45RO+, CD62L+, CD28+, CD95+, CCR7+, CD27+, CD127+.
  • the endogenous locus is within an endogenous TCR gene.
  • the TCR gene sequence encodes for a TCR that recognizes a tumor antigen.
  • the tumor antigen is a neoantigen.
  • the tumor antigen is a patient specific neoantigen.
  • the TCR gene sequence is a patient specific TCR gene sequence.
  • the process further comprises culturing the cell.
  • the culturing is conducted in the presence of at least one cytokine.
  • the culturing is conducted in the presence of IL2, IL7, IL15, or any combination thereof.
  • the culturing is conducted in the presence of IL7 and IL15.
  • the presently disclosed subject matter provides a method of modifying a cell, the method comprising introducing into a cell a homologous recombination (HR) template nucleic acid sequence, recombining the HR template nucleic acid into an endogenous locus of the cell, and disrupting a TET2 locus of the cell.
  • the HR template comprises first and second homology arms homologous to first and second target nucleic acid sequences, and a TCR gene sequence positioned between the first and second homology arms.
  • the HR template comprises a first 2A-coding sequence positioned upstream of the TCR gene sequence and a second 2A-coding sequence positioned downstream of the TCR gene sequence, wherein the first and second 2A-coding sequences code for the same amino acid sequence that are codon-diverged relative to each other.
  • the 2A-coding sequence is a P2A-coding sequence.
  • a sequence coding for the amino acid sequence Gly Ser Gly is positioned immediately upstream of the 2A-coding sequences.
  • the HR template comprises a sequence coding for a Furin cleavage site positioned upstream of the second 2A-coding sequence.
  • the first and second homology arms are each from about 300 bases to about 2,000 bases in length. In certain embodiments, the first and second homology arms are each from about 600 bases to about 2,000 bases in length.
  • the HR template further comprises a signal sequence positioned between the first 2A-coding sequence and the TCR gene sequence. In certain embodiments, the HR template comprises a second TCR sequence positioned between the second 2A-coding sequence and the second homology arm.
  • the HR template comprises a first signal sequence positioned between the first 2A-coding sequence and the first TCR gene sequence, and a second signal sequence positioned between the second 2A-coding sequence and the second TCR gene sequence, wherein the first and the second signal sequences encode for the same amino acid sequence and are codon diverged relative to each other.
  • the signal sequence is a human growth hormone signal sequence.
  • the HR template is non-viral. In certain embodiments, the HR template is a circular DNA. In certain embodiments, the HR template is a linear DNA. In certain embodiments, the introducing occurs via electroporation.
  • the recombining comprises cleavage of the endogenous locus by a nuclease, and recombination of the HR template nucleic acid sequence into the endogenous locus by homology directed repair.
  • the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • the nuclease comprises a gRNA.
  • the disrupting comprises introducing a substitution, a deletion, an insertion, or any combination thereof. In certain embodiments, the disrupting comprises introducing a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof. In certain embodiments, the disrupting results in a non-functional TET2 protein. In certain embodiments, the disrupting results in knockout of the TET2 gene expression.
  • the disrupting comprises cleavage of the TET2 locus by a nuclease.
  • the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • the nuclease comprises a gRNA.
  • the gRNA comprises a sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • the nuclease is expressed by a vector.
  • the gRNA is expressed by a vector.
  • the vector is a viral vector.
  • the vector is a non-viral vector.
  • the disrupting of the TET2 locus enhances cell persistence. In certain embodiments, the disrupting of the TET2 locus enhances memory cell differentiation.
  • the cell is a primary cell. In certain embodiments, the cell is a patient-derived cell. In certain embodiments, the cell is a lymphocyte. In certain embodiments, the cell is a T cell. In certain embodiments, the T cell is a patient-derived cell. In certain embodiments, the cell is a young T cell. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95-, CCR7+, and CD27+. In certain embodiments, the cell is CD45RA+, CD62L+, CD28+, CD95+, CD27+, CCR7+. In certain embodiments, the cell is CD45RO+, CD62L+, CD28+, CD95+, CCR7+, CD27+, CD127+.
  • the endogenous locus is within an endogenous TCR gene.
  • the TCR gene sequence encodes for a TCR that recognizes a tumor antigen.
  • the tumor antigen is a neoantigen.
  • the tumor antigen is a patient specific neoantigen.
  • the TCR gene sequence is a patient specific TCR gene sequence.
  • the method further comprises culturing the cell.
  • the culturing is conducted in the presence of at least one cytokine.
  • the culturing is conducted in the presence of IL2, IL7, IL15, or any combination thereof.
  • the culturing is conducted in the presence of IL7 and IL15.
  • the presently disclosed subject matter provides a method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a cell disclosed herein.
  • a non-myeloablative lymphodepletion regimen is administered to the subject.
  • the cancer is a solid tumor. In certain embodiments, the cancer is liquid tumor.
  • the solid tumor is selected from the group consisting of melanoma, thoracic cancer, lung cancer, ovarian cancer, breast cancer, pancreatic cancer, head and neck cancer, prostate cancer, gynecological cancer, central nervous system cancer, cutaneous cancer, HPV+ cancer, esophageal cancer, thyroid cancer, gastric cancer, hepatocellular cancer, cholangiocarcinomas, renal cell cancers, testicular cancer, sarcomas, and colorectal cancer.
  • the liquid tumor is selected from the group consisting of follicular lymphoma, leukemia, and multiple myeloma.
  • the presently disclosed subject matter provides a composition comprising an effective amount of a cell disclosed herein.
  • the composition is a pharmaceutical composition that further comprises a pharmaceutically acceptable excipient.
  • the composition is administered to a patient in need thereof for the treatment of cancer.
  • the composition comprises a cryopreservation agent.
  • the composition comprises serum albumin.
  • the composition comprises Plasma-Lyte A, HSA, and CryoStor CS10.
  • the presently disclosed subject matter provides a kit comprising a cell, reagents for performing a method, or a composition disclosed herein.
  • the kit further comprises written instructions for treating a cancer.
  • FIG. 1 provides a high-level diagram of the knock-out and knock-in at the endogenous TCR locus and the knock-out of the TET2 gene accomplished by the gene editing technology described herein.
  • FIGS. 2A-2C show an example of a NeoE TCR cassette and gene editing methods that can be used to make NeoTCR Products.
  • FIG. 2A shows a schematic representing the general targeting strategy used for integrating neoantigen-specific TCR constructs (neoTCRs) into the TCR ⁇ locus.
  • FIGS. 2B and 2C show a neoantigen-specific TCR construct design used for integrating a NeoTCR into the TCR ⁇ locus wherein the cassette is shown with signal sequences (“SS”), protease cleavage sites (“P”), and 2A peptides (“2A”).
  • SS signal sequences
  • P protease cleavage sites
  • 2A 2A peptides
  • FIG. 2B shows a target TCR ⁇ locus (endogenous TRAC, top panel) and its CRISPR Cas9 target site (horizontal stripes, cleavage site designated by the arrow), and the circular plasmid HR template (bottom panel) with the polynucleotide encoding the neoTCR, which is located between left and right homology arms (“LHA” and “RHA” respectively) prior to integration.
  • FIG. 2C shows the integrated neoTCR in the TCR ⁇ locus (top panel), the transcribed and spliced neoTCR mRNA (middle panel), and translation and processing of the expressed neoTCR (bottom panel).
  • FIG. 3 shows the results of an In-Out PCR confirming precise target integration of the NeoE TCR cassette.
  • Agarose gels show the results of a PCR using primers specific to the NeoE TCR cassette and relative site generate products of the expected size only for cells treated with both nuclease and DNA template (knock-out-knock-in (KOKI) and knock-out-knock-in-knock-out (KOKIKO)), demonstrating site-specific and precise integration.
  • FIG. 4A shows results from a FACS experiment showing that the endogenous TCR has reduced signal and that there is a strong NeoE TCR signal in cells that were electroporated with the NeoE TCR cassette.
  • FIG. 4B shows the results from a series of multiple transfection experiments with the NeoE TCR cassette showing a high degree of reproducibility between experiments.
  • FIGS. 5A-5E depict five (5) exemplary RNP knockout strategies for knocking out the TET2 gene.
  • FIGS. 5A and 5E depict sgRNAs that target the negative strand.
  • FIGS. 5B, 5C, and 5D depict sgRNAs that target the positive strand.
  • FIGS. 6A and 6B show agarose gels of amplified DNA extracted from lysed TET2 gRNA-Cas9 RNP edited CD4 and CD8 T cells.
  • the primers used for the amplification are provided in Table 3.
  • FIG. 6A shows PCR amplicons that were uncut.
  • FIG. 6B shows PCR amplicons that were cut by incubation with T7 endonuclease I (NEB).
  • the lanes of both FIG. 6A and FIG. 6B are: 1. Marker, 2. WT (TET2_Fwd1, TET2_Rev1), 3. WT (TET2_Fwd2, TET2_Rev2), 4. gRNA1 (TET2_Fwd1, TET2_Rev1), 5.
  • gRNA2 (TET2_Fwd2, TET2_Rev2), 6. gRNA3 (TET2_Fwd2, TET2_Rev2), 7. gRNA4 (TET2_Fwd1, TET2_Rev1), 8. gRNA5 (TET2_Fwd1, TET2_Rev1).
  • FIGS. 7A-7E show that coverage of the PCR amplicons was robust for all amplicons surrounding the guide site.
  • FIG. 7A shows results of gRNA 1 (SEQ ID NO:1).
  • FIG. 7B shows results of gRNA 4 (SEQ ID NO:4).
  • FIG. 7C shows results of gRNA 5 (SEQ ID NO:5).
  • FIG. 7D shows results of gRNA 3 (SEQ ID NO:3).
  • FIG. 7E shows results of gRNA 2 (SEQ ID NO:2).
  • FIGS. 8A and 8B show that sgRNA 3 (SEQ ID NO:3) provides the best disruption of TET2 and does not interfere with the neoTCR gene editing and the insertion of a neoTCR.
  • FIG. 8A shows the indel characterization and
  • FIG. 8B shows the gene editing (insertion of the neoTCR) rates.
  • the gene editing insertion of the neoTCR as provided in FIG. 8B is measured by dextramer binding to the gene edited cells. Because the dextramer specifically binds to the neoTCR, binding is a direct correlation to neoTCR expression.
  • FIG. 9 shows that there is no appreciable reduction in 5-hmC in the absence of TET2 (i.e., in TET2 Products) with or without 1.5h stimulation with cognate comPACT plate coating.
  • FIG. 10 shows the TET2 Products had the equivalent expression of the TCF7 and TBET transcription factors as NeoTCR Products (i.e., cells that did not have a TET2 deletion).
  • the cells used in this flow cytometry experiment were resting edited cells.
  • FIGS. 11A and 11B show that TET2 Disruption by gRNA3 results in reduced terminal effector differentiation as evidenced by percent IFN ⁇ + cells ( FIG. 11A ) and percent CD107a+ cells ( FIG. 11B ).
  • FIGS. 12A and 12B there are no differences between the tumor cell killing ability of TET2 Products and NeoTCR Products kept in culture for 14-15 days.
  • IncuCyte assays with PACT035-TCR089 neoTCR edited T cells with and without TET2 gRNA3 were co-cultured with SW620 COX6C-R20Q tumor cells ( FIG. 12A ) or SW620 tumor cells lacking the COX6C-R20Q mutation ( FIG. 12B ).
  • the R20Q mutation directly correlates with TCR089 such that TCR089 is designed to kill cells that express the R20Q mutation.
  • FIGS. 13A and 13B show that TET2 Products maintain killing activity longer than NeoTCR Products (cells without a knockout of the TET2 gene).
  • NeoTCR Products PACT035-TCR089 as shown in the figures
  • TET2 Products PACT035-TCR089 TET2 gRNA 3 as shown in the figures
  • IncuCyte assays with NeoTCR Products PACT035-TCR089) and TET2 Products (PACT035-TCR089 TET2 gRNA 3) were co-cultured with SW620 COX6C-R20Q tumor cells ( FIG. 13A ) or SW620 tumor cells lacking the COX6C-R20Q mutation ( FIG. 13B ).
  • FIGS. 14A and 14B shows that TET2 disruption enhances CD8 memory cell differentiation.
  • Geometric mean fluorescence intensity of surface markers associated with memory and exhaustion among CD8+ dextramer+neoTCR edited T cells with or without TET2 gRNA3 stimulated with cognate comPACT for 7 days is shown for NeoTCR Products (PACT035-TCR089 as shown in the figures) and TET2 Products (PACT035-TCR089 TET2 gRNA 3 as shown in the figures).
  • the CCR7 and CD27 plots shown in the FIGS. 14A and 14B show that TET2 distruption enhances CD8 memory cell differentiation. Specifically, CCR7 and CD27 are highly expressed on central memory CD8 T cells. The fact that the TET2 Cells increase the expression (higher MFI) compared to NeoTCR Cells is represents this effect.
  • FIGS. 15A-15D show that expression of TOX ( FIGS. 15B and 15D ) and TCF7 ( FIGS. 15A and 15C ) were unchanged between NeoTCR Products (PACT035-TCR089 as shown in the figures) and TET2 Products (PACT035-TCR089 TET2 gRNA 3 as shown in the figures).
  • the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, e.g., within 5-fold or within 2-fold, of a value.
  • Cancer and “Tumor” are used interchangeably herein.
  • the terms “Cancer” or “Tumor” refer to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms are further used to refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
  • Cancer can affect a variety of cell types, tissues, or organs, including but not limited to an organ selected from the group consisting of bladder, bone, brain, breast, cartilage, glia, esophagus, fallopian tube, gallbladder, heart, intestines, kidney, liver, lung, lymph node, nervous tissue, ovaries, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, and vagina, or a tissue or cell type thereof.
  • Cancer includes cancers, such as sarcomas, carcinomas, or plasmacytomas (malignant tumor of the plasma cells). Examples of cancer include, but are not limited to, those described herein.
  • the terms “Cancer” or “Tumor” and “Proliferative Disorder” are not mutually exclusive as used herein.
  • “Dextramer” as used herein means a multimerized neoepitope-HLA complex that specifically binds to its cognate NeoTCR.
  • neoantigen As used herein, the terms “neoantigen”, “neoepitope” or “neoE” refer to a newly formed antigenic determinant that arises, e.g., from a somatic mutation(s) and is recognized as “non-self”
  • NeoTCR and “NeoE TCR” as used herein mean a neoepitope-specific T cell receptor that is introduced into a T cell, e.g., by gene editing methods.
  • NeoTCR cells as used herein means one or more cells precision engineered to express one or more NeoTCRs.
  • the cells are T cells.
  • the T cells are CD8+ and/or CD4+ T cells.
  • the CD8+ and/or CD4+ T cells are autologous cells from the patient for whom a NeoTCR Product will be administered.
  • the terms “NeoTCR cells” and “NeoTCR-P1 T cells” and “NeoTCR-P1 cells” are used interchangeably herein.
  • NeoTCR cells are not engineered to knockout expression of the TET2 gene.
  • NeoTCR Product as used herein means a pharmaceutical formulation comprising one or more NeoTCR cells.
  • NeoTCR Product consists of autologous precision genome-engineered CD8+ and CD4+ T cells.
  • expression of the endogenous TCR is eliminated and replaced by a patient-specific NeoTCR isolated from peripheral CD8+ T cells targeting the tumor-exclusive neoepitope.
  • the resulting engineered CD8+ or CD4+ T cells express NeoTCRs on their surface of native sequence, native expression levels, and native TCR function. The sequences of the NeoTCR external binding domain and cytoplasmic signaling domains are unmodified from the TCR isolated from native CD8+ T cells.
  • NeoTCR gene expression is driven by the native endogenous TCR promoter positioned upstream of where the NeoTCR gene cassette is integrated into the genome. Through this approach, native levels of NeoTCR expression are observed in unstimulated and antigen-activated T cell states.
  • the NeoTCR Product manufactured for each patient represents a defined dose of autologous CD8+ and/or CD4+ T cells that are precision genome engineered to express a single neoE-specific TCR cloned from neoE-specific CD8+ T cells individually isolated from the peripheral blood of that same patient.
  • NeoTCR Products are not engineered to knockout expression of the TET2 gene.
  • NeoTCR Viral Product as used herein has the same definition of NeoTCR Product except that the genome engineering is performed using viral mediated methods.
  • “Pharmaceutical Formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. For clarity, DMSO at quantities used in a NeoTCR Product is not considered unacceptably toxic.
  • a “subject,” “patient,” or an “individual” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
  • the mammal is human.
  • TCR as used herein means T cell receptor.
  • TET2 is a gene that encodes the protein methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine.
  • TET2 is also referred to as Tet methylcytosine dioxygenase 2, FU20032, KIAA1546, MGC125715, probably methylcytosine dioxygenase TET2, probably mehtvic tosine dioxygenase TET2 isoform a, probably methylcytosine dioxygenase TET2 isoform b, tet oncogene family member 2, and TET2_HUMAN.
  • TET2 cells as used herein means one or more cells precision engineered to express one or more NeoTCRs and a knockout of the TET2 gene.
  • the cells are T cells.
  • the T cells are CD8+ and/or CD4+ T cells.
  • the CD8+ and/or CD4+ T cells are autologous cells from the patient for whom a TET2 Product will be administered.
  • TET2 NeoTCR Product as used herein means a product comprising TET2 cells.
  • TET2 Products of this disclosure are used to delay development of a proliferative disorder (e.g., cancer) or to slow the progression of such disease.
  • a proliferative disorder e.g., cancer
  • TET2 Products of the disclosure is used to delay the development of a proliferative disorder (e.g., cancer) or to slow the progression of such disease.
  • a proliferative disorder e.g., cancer
  • tumor antigen refers to an antigen (e.g., a polypeptide) that is uniquely or differentially expressed on a tumor cell compared to a normal or non-neoplastic cell.
  • a tumor antigen includes any polypeptide expressed by a tumor that is capable of activating or inducing an immune response via an antigen-recognizing receptor or capable of suppressing an immune response via receptor-ligand binding.
  • 2A and “2A peptide” are used interchangeably herein and mean a class of 18-22 amino acid long, viral, self-cleaving peptides that are able to mediate cleavage of peptides during translation in eukaryotic cells.
  • T2A The T2A peptide was first identified in the Thosea asigna virus 2A.
  • the P2A peptide was first identified in the porcine teschovirus-1 2A.
  • the E2A peptide was first identified in the equine rhinitis A virus.
  • the F2A peptide was first identified in the foot-and-mouth disease virus.
  • the self-cleaving mechanism of the 2A peptides is a result of ribosome skipping the formation of a glycyl-prolyl peptide bond at the C-terminus of the 2A.
  • the 2A peptides have a C-terminal conserved sequence that is necessary for the creation of steric hindrance and ribosome skipping.
  • the ribosome skipping can result in one of three options: 1) successful skipping and recommencement of translation resulting in two cleaved proteins (the upstream of the 2A protein which is attached to the complete 2A peptide except for the C-terminal proline and the downstream of the 2A protein which is attached to one proline at the N-terminal; 2) successful skipping but ribosome fall-off that results in discontinued translation and only the protein upstream of the 2A; or 3) unsuccessful skipping and continued translation (i.e., a fusion protein).
  • endogenous refers to a nucleic acid molecule or polypeptide that is normally expressed in a cell or tissue.
  • exogenous refers to a nucleic acid molecule or polypeptide that is not endogenously present in a cell.
  • exogenous would therefore encompass any recombinant nucleic acid molecule or polypeptide expressed in a cell, such as foreign, heterologous, and over-expressed nucleic acid molecules and polypeptides.
  • exogenous nucleic acid is meant a nucleic acid not present in a native wild-type cell; for example an exogenous nucleic acid may vary from an endogenous counterpart by sequence, by position/location, or both.
  • an exogenous nucleic acid may have the same or different sequence relative to its native endogenous counterpart; it may be introduced by genetic engineering into the cell itself or a progenitor thereof, and may optionally be linked to alternative control sequences, such as a non-native promoter or secretory sequence.
  • T MSC memory stem cells
  • T CM central memory cells
  • NeoTCRs are cloned in autologous CD8+ and CD4+ T cells from the same patient with cancer by precision genome engineered (using a DNA-mediated (non-viral) method as described in FIGS. 2A-2C ) to express the neoTCR.
  • the NeoTCRs are tumor specific and identified in cancer patients. These NeoTCRs are then cloned and the cloned NeoTCRs are inserted into the cancer patient's T cells.
  • NeoTCR expressing T cells are then expanded in a manner that preserves a “young” T cell phenotypes, resulting in a NeoTCR-P1 product (i.e., a NeoTCR Product) in which the majority of the T cells exhibit T memory stem cell and T central memory phenotypes.
  • a NeoTCR-P1 product i.e., a NeoTCR Product
  • NeoTCR Product consisting significantly of ‘young’ T cell phenotypes, has the potential to benefit patients with cancer, through improved engraftment potential, prolonged persistence post-infusion, and rapid differentiation into effector T cells to eradicate tumor cells throughout the body.
  • NeoTCR Product manufactured with T cells from patients with cancer. Comparable gene editing efficiencies and functional activities, as measured by antigen-specificity of T cell killing activity, proliferation, and cytokine production, were observed demonstrating that the manufacturing process described herein is successful in generating product with T cells from patients with cancer as starting material.
  • the NeoTCR Product manufacturing process involves electroporation of dual ribonucleoprotein species of CRISPR-Cas9 nucleases bound to guide RNA sequences, with each species targeting the genomic TCR ⁇ and the genomic TCR ⁇ loci.
  • the specificity of targeting Cas9 nucleases to each genomic locus has been previously described in the literature as being highly specific.
  • Comprehensive testing of the NeoTCR Product was performed in vitro and in silico analyses to survey possible off-target genomic cleavage sites, using COSMID and GUIDE-seq, respectively. Multiple NeoTCR Product or comparable cell products from healthy donors were assessed for cleavage of the candidate off-target sites by deep sequencing, supporting the published evidence that the selected nucleases are highly specific.
  • NeoTCR Product The comprehensive assessment of the NeoTCR Product and precision genome engineering process indicates that the NeoTCR Product will be well tolerated following infusion back to the patient.
  • NeoTCR T cells i.e., NeoTCR Products
  • the engineering method is not restricted to the use in T cells and has also been applied successfully to other primary cell types, including natural killer and hematopoietic stem cells.
  • NeoTCR Products described above are further modified to knock out TET2 expression from the cells of the product (i.e., a TET2 Product).
  • a TET2 Product i.e., a TET2 Product.
  • NeoTCRs are cloned in autologous CD8+ and CD4+ T cells from the same patient with cancer by precision genome engineered (using a DNA-mediated (non-viral) method as described in FIGS. 2A-2C ) to express the neoTCR.
  • the TET2 gene is disrupted using a gRNA to knockout expression of TET2 in the same reaction as the reaction used to knock out the TCR ⁇ and insertion of the neoTCR ⁇ and neoTCR ⁇ (see FIG. 1 ).
  • the knock out the TCR ⁇ , insertion of the neoTCR ⁇ and neoTCR ⁇ , and knockout of TET2 are performed concurrently in the same reaction.
  • the TET2 gene is disrupted using a gRNA to knockout expression of TET2 in a different reaction as the reaction used to knock out the TCR ⁇ and insertion of the neoTCR ⁇ and neoTCR ⁇ (see FIG. 1 ).
  • the knockout of the TCR ⁇ and insertion of the neoTCR ⁇ and neoTCR ⁇ are performed in separate and consecutive reactions from the knockout of TET2.
  • the knockout of the TCR ⁇ and insertion of the neoTCR ⁇ and neoTCR ⁇ are performed in a first reaction and the knockout of TET2 is performed in a second reaction.
  • the knockout of TET2 is performed in a first reaction and the knockout of the TCR ⁇ and insertion of the neoTCR ⁇ and neoTCR ⁇ are performed in a second reaction.
  • the TET2 Products comprise cells that were engineered to express one or more NeoTCRs using viral methods (i.e., NeoTCR Viral Product) and a knockout of the TET2 gene.
  • the cells of the NeoTCR Viral Product are further engineered to knockout the TET2 gene using non-viral methods.
  • the cells of the NeoTCR Viral Product are further engineered to knockout the TET2 gene using viral methods.
  • the TET2 Product manufacturing process involves electroporation of 1) dual ribonucleoprotein species of CRISPR-Cas9 nucleases bound to guide RNA sequences, with each species targeting the genomic TCR ⁇ and the genomic TCR ⁇ loci, and 2) a ribonucleoprotein species of CRISPR-Cas9 nucleases bound to guide RNA sequences that target the TET2 gene.
  • the specificity of targeting Cas9 nucleases to each genomic locus has been previously described in the literature as being highly specific.
  • Comprehensive testing of the TET2 Product can be performed in vitro and in silico analyses to survey possible off-target genomic cleavage sites, using COSMID and GUIDE-seq, respectively. In certain embodiments, testing can be performed using COSMID-based in silico prediction of off-targets and GUIDE-seq-based in vitro prediction of off-targets, followed by testing of those putative off-targets by targeted deep sequencing.
  • TET2 cells are expanded in a manner that preserves a “young” T cell phenotypes, resulting in a TET2 Product in which the majority of the T cells exhibit T memory stem cell and T central memory phenotypes
  • TET2 Product consisting significantly of ‘young’ T cell phenotypes, has the potential to benefit patients with cancer, through improved engraftment potential, prolonged persistence post-infusion, and rapid differentiation into effector T cells to eradicate tumor cells throughout the body.
  • the TET2 cells of the TET2 Products predominantly comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 25% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 30% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 35% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm).
  • At least 40% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 45% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 50% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 55% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm).
  • At least 60% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 65% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 70% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm). In certain embodiments, at least 75% of the TET2 cells of the TET2 Products comprise memory stem cells (Tmsc) and/or central memory cells (Tcm).
  • Tmsc memory stem cells
  • Tcm central memory cells
  • Tmsc are characterized as cells that are CD45RA+CD62L+, CD28+CD95+, and CCR7+CD27+.
  • Tcm are characterized as cells that are CD45RO+CD62L+, CD28+CD95+, and CCR7+CD27+CD127+. Both Tmsc and Tcm are characterized as having weak effector T cell function, robust proliferation, robust engraftment, and long telomeres.
  • the present disclosure relates, in part, on the production of engineered “young” T cells.
  • the present disclosure comprises methods for producing antigen-specific cells, e.g., T cells, ex vivo, comprising activating, engineering, and expanding antigen-specific cells originally obtained from a subject or isolated from such sample.
  • the methods for activating cells comprise the steps of activating the TCR/CD3 complex.
  • the T cells can be incubated and/or cultured with CD3 agonists, CD28 agonists, or a combination thereof.
  • engineered activated antigen-specific cells can be expanded by culturing the engineered activated antigen-specific cells, e.g., T cells, with cytokines, chemokine, soluble peptides, or combination thereof.
  • the engineered activated antigen-specific cells e.g., engineered activated T cells
  • the cytokines can be IL2, IL7, IL15, or combinations thereof.
  • engineered activated antigen-specific cells e.g., engineered activated T cells, can be cultured with IL7 and IL15.
  • the cytokine used in connection with the engineered activated antigen-specific cell, e.g., engineered activated T cell, culture can be present at a concentration from about 1 ⁇ g/ml to about 1 g/ml, from about 1 ng/ml to about 1 g/ml, from about 1 ⁇ g/ml to about 1 g/ml, or from about 1 mg/ml to about 1 g/ml, and any values in between.
  • compositions of the TET2 Product are prepared by combining the TET2 cells in a solution that can preserve the ‘young’ phenotype of the cells in a cryopreserved state.
  • Table 1 provides an example of one such pharmaceutical formulation.
  • pharmaceutical formulations of the TET2 Product can be prepared by combining the TET2 cells in a solution that can preserve the ‘young’ phenotype of the cells without the need to freeze or cryopreserve the product (i.e., the TET2 Product is maintained in an aqueous solution or as a non-frozen/cryopreserved cell pellet).
  • cryopreservation solution or the aqueous storage solution (if the TET2 Product is not cryopreserved).
  • Any cryopreservation agent and/or media can be used to cryopreserve the TET2 Product, including but not limited to CryoStor, CryoStor CS5, CELLBANKER, and custom cryopreservation media that optionally include DMSO.
  • the present disclosure involves, in part, methods of engineering human cells, e.g., engineered T cells or engineered human stem cells.
  • such engineering involves genome editing.
  • genome editing can be accomplished with nucleases targeting one or more endogenous loci, e.g., TCR alpha (TCR ⁇ ) locus and TCR beta (TCR ⁇ ) locus, along with the TET2 locus.
  • the nucleases can generate single-stranded DNA nicks or double-stranded DNA breaks in an endogenous target sequence.
  • the nuclease can target coding or non-coding portions of the genome, e.g., exons, introns.
  • the nucleases contemplated herein comprise homing endonuclease, meganuclease, megaTAL nuclease, transcription activator-like effector nuclease (TALEN), zinc-finger nuclease (ZFN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas nuclease.
  • the nucleases can themselves be engineered, e.g., via the introduction of amino acid substitutions and/or deletions, to increase the efficiency of the cutting activity.
  • a CRISPR/Cas nuclease system is used to engineer human cells.
  • the CRISPR/Cas nuclease system comprises a Cas nuclease and one or more RNAs that recruit the Cas nuclease to the endogenous target sequence, e.g., single guide RNA.
  • the Cas nuclease and the RNA are introduced in the cell separately, e.g. using different vectors or compositions, or together, e.g., in a polycistronic construct or a single protein-RNA complex.
  • the Cas nuclease is Cas9 or Cas12a.
  • the Cas9 polypeptide is obtained from a bacterial species including, without limitation, Streptococcus pyogenes or Neisseria menengitidis . Additional examples of CRISPR/Cas systems are known in the art. See Adli, Mazhar. “The CRISPR tool kit for genome editing and beyond.” Nature communications vol. 9,1 1911 (2016), herein incorporated by reference for all that it teaches.
  • genome editing occurs at one or more genome loci that regulate immunological responses.
  • the loci include, without limitation, TCR alpha (TCR ⁇ ) locus, TCR beta (TCR ⁇ ) locus, TCR gamma (TCR ⁇ ), TCR delta (TCR ⁇ ), and TET2.
  • TCR ⁇ TCR alpha
  • TCR ⁇ TCR beta
  • TCR ⁇ TCR gamma
  • TCR ⁇ TCR delta
  • TET2 locus one of the loci.
  • genome editing is performed by using non-viral delivery systems.
  • a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., Proc. Natl. Acad. Sci. U.S.A. 84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990; Brigham et al., Am. J. Med. Sci.
  • Transplantation of normal genes into the affected tissues of a subject can also be accomplished by transferring a normal nucleic acid into a cultivatable cell type ex vivo (e.g., an autologous or heterologous primary cell or progeny thereof), after which the cell (or its descendants) are injected into a targeted tissue or are injected systemically.
  • a cultivatable cell type ex vivo e.g., an autologous or heterologous primary cell or progeny thereof
  • genome editing is performed by using viral delivery systems.
  • the viral methods include targeted integration (including but not limited to AAV) and random integration (including but not limited to lentiviral approaches).
  • the viral delivery would be accomplished without integration of the nuclease.
  • the viral delivery system can be Lentiflash or another similar delivery system.
  • the present disclosure provides genome editing of a cell by introducing and recombining a homologous recombination (HR) template nucleic acid sequence into an endogenous locus of a cell.
  • HR homologous recombination
  • the HR template nucleic acid sequence is linear.
  • the HR template nucleic acid sequence is circular.
  • the circular HR template can be a plasmid, minicircle, or nanoplasmid.
  • the HR template nucleic acid sequence comprises a first and a second homology arms.
  • the homology arms can be of about 300 bases to about 2,000 bases. For example, each homology arm can be 1,000 bases.
  • the homology arms can be homologous to a first and second endogenous sequences of the cell.
  • the endogenous locus is a TCR locus.
  • the first and second endogenous sequences are within a TCR alpha locus or a TCR beta locus.
  • the HR template comprises a TCR gene sequences.
  • the TCR gene sequence is a patient specific TCR gene sequence.
  • the TCR gene sequence is tumor-specific.
  • the TCR gene sequence can be identified and obtained using the methods described in PCT/US2020/017887, the content of which is herein incorporated by reference.
  • the HR template comprises a TCR alpha gene sequence and a TCR beta gene sequence.
  • the HR template is a polycistronic polynucleotide.
  • the HR template comprises sequences encoding for flexible polypeptide sequences (e.g., Gly-Ser-Gly sequence).
  • the HR template comprises sequences encoding an internal ribosome entry site (IRES).
  • the HR template comprises a 2A peptide (e.g., P2A, T2A, E2A, and F2A). Additional information on the HR template nucleic acids and methods of modifying a cell thereof can be found in International Patent Application no. PCT/US2018/058230, the content of which is herein incorporated by reference.
  • the presently disclosed subject matter provides methods for inducing and/or increasing an immune response in a subject in need thereof.
  • the TET2 Products can be used for treating and/or preventing a cancer in a subject.
  • the TET2 Products can be used for prolonging the survival of a subject suffering from a cancer.
  • the TET2 Products can also be used for treating and/or preventing a cancer in a subject.
  • the TET2 Products can also be used for reducing tumor burden in a subject.
  • Such methods comprise administering the TET2 Products in an amount effective or a composition (e.g., a pharmaceutical composition) comprising thereof to achieve the desired effect, be it palliation of an existing condition or prevention of recurrence.
  • the amount administered is an amount effective in producing the desired effect.
  • An effective amount can be provided in one or a series of administrations.
  • An effective amount can be provided in a bolus or by continuous perfusion.
  • an effective amount of the TET2 Products are delivered through intravenous (IV) administration.
  • the TET2 Products are delivered through IV administration in a single administration.
  • the TET2 Products are delivered through IV administration in multiple administrations.
  • the TET2 Products are delivered through IV administration in two or more administrations.
  • the TET2 Products are delivered through IV administration in two administrations.
  • the TET2 Products are delivered through IV administration in three administrations.
  • the presently disclosed subject matter provides methods for treating and/or preventing cancer in a subject.
  • the method comprises administering an effective amount of the TET2 Products to a subject having cancer.
  • Non-limiting examples of cancer include blood cancers (e.g. leukemias, lymphomas, and myelomas), ovarian cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, throat cancer, melanoma, neuroblastoma, adenocarcinoma, glioma, soft tissue sarcoma, and various carcinomas (including prostate and small cell lung cancer).
  • blood cancers e.g. leukemias, lymphomas, and myelomas
  • ovarian cancer breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, throat cancer, melanoma, neuroblastoma, adenocarcinoma, glioma, soft tissue sarcoma, and various carcinomas (including prostate and small cell lung cancer
  • Suitable carcinomas further include any known in the field of oncology, including, but not limited to, astrocytoma, fibrosarcoma, myxosarcoma, liposarcoma, oligodendroglioma, ependymoma, medulloblastoma, primitive neural ectodermal tumor (PNET), chondrosarcoma, osteogenic sarcoma, pancreatic ductal adenocarcinoma, small and large cell lung adenocarcinomas, chordoma, angiosarcoma, endotheliosarcoma, squamous cell carcinoma, bronchoalveolarcarcinoma, epithelial adenocarcinoma, and liver metastases thereof, lymphangiosarcoma, lymphangioendotheliosarcoma, hepatoma, cholangiocarcinoma, synovioma, mesothelioma, Ewing's
  • the cancer is selected from the group consisting of blood cancers (e.g. leukemias, lymphomas, and myelomas), ovarian cancer, prostate cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, and throat cancer.
  • blood cancers e.g. leukemias, lymphomas, and myelomas
  • ovarian cancer e.g. leukemias, lymphomas, and myelomas
  • the presently disclosed young T cells and compositions comprising thereof can be used for treating and/or preventing blood cancers (e.g., leukemias, lymphomas, and myelomas) or ovarian cancer, which are not amenable to conventional therapeutic interventions.
  • the cancer is a solid cancer or a solid tumor.
  • the solid tumor or solid cancer is selected from the group consisting of glioblastoma, prostate adenocarcinoma, kidney papillary cell carcinoma, sarcoma, ovarian cancer, pancreatic adenocarcinoma, rectum adenocarcinoma, colon adenocarcinoma, esophageal carcinoma, uterine corpus endometrioid carcinoma, breast cancer, skin cutaneous melanoma, lung adenocarcinoma, stomach adenocarcinoma, cervical and endocervical cancer, kidney clear cell carcinoma, testicular germ cell tumors, and aggressive B-cell lymphomas.
  • the subjects can have an advanced form of disease, in which case the treatment objective can include mitigation or reversal of disease progression, and/or amelioration of side effects.
  • the subjects can have a history of the condition, for which they have already been treated, in which case the therapeutic objective will typically include a decrease or delay in the risk of recurrence.
  • Suitable human subjects for therapy typically comprise two treatment groups that can be distinguished by clinical criteria.
  • Subjects with “advanced disease” or “high tumor burden” are those who bear a clinically measurable tumor.
  • a clinically measurable tumor is one that can be detected on the basis of tumor mass (e.g., by palpation, CAT scan, sonogram, mammogram or X-ray; positive biochemical or histopathologic markers on their own are insufficient to identify this population).
  • a pharmaceutical composition is administered to these subjects to elicit an anti-tumor response, with the objective of palliating their condition.
  • reduction in tumor mass occurs as a result, but any clinical improvement constitutes a benefit.
  • Clinical improvement includes decreased risk or rate of progression or reduction in pathological consequences of the tumor.
  • the TET2 Products can be used in combination with articles of manufacture. Such articles of manufacture can be useful for the prevention or treatment of proliferative disorders (e.g., cancer).
  • articles of manufacture include but are not limited to containers (e.g., infusion bags, bottles, storage containers, flasks, vials, syringes, tubes, and IV solution bags) and a label or package insert on or associated with the container.
  • the containers may be made of any material that is acceptable for the storage and preservation of the TET2 cells within the TET2 Products.
  • the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.
  • the container may be a CryoMACS freezing bag.
  • the label or package insert indicates that the TET2 Products are used for treating the condition of choice and the patient of origin.
  • the patient is identified on the container of the TET2 Product because the TET2 Products is made from autologous cells and engineered as a patient-specific and individualized treatment.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; and 2) a second container with the same TET2 Product as the first container contained therein.
  • additional containers with the same TET2 Product as the first and second containers may be prepared and made.
  • additional containers containing a composition comprising a different cytotoxic or otherwise therapeutic agent may also be combined with the containers described above.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; and 2) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture may comprise: 1) a first container with two TET2 Products contained therein; and 2) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; and 3) optionally a third container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the first and second TET2 Products are different TET2 Products.
  • the first and second TET2 Products are the same TET2 Products.
  • the article of manufacture may comprise: 1) a first container with three TET2 Products contained therein; and 2) optionally a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; 3) a third container with a third TET2 Product contained therein; and 4) optionally a fourth container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the first, second, and third TET2 Products are different TET2 Products.
  • the first, second, and third TET2 Products are the same TET2 Products.
  • two of the first, second, and third TET2 Products are the same TET2 Products.
  • the article of manufacture may comprise: 1) a first container with four TET2 Products contained therein; and 2) optionally a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; 3) a third container with a third TET2 Product contained therein; 4) a fourth container with a fourth TET2 Product contained therein; and 5) optionally a fifth container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the first, second, third, and fourth TET2 Products are different TET2 Products.
  • the first, second, third, and fourth TET2 Products are the same TET2 Products.
  • two of the first, second, third, and fourth TET2 Products are the same TET2 Products.
  • three of the first, second, third, and fourth TET2 Products are the same TET2 Products.
  • the article of manufacture may comprise: 1) a first container with five or more TET2 Products contained therein; and 2) optionally a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; 3) a third container with a third TET2 Product contained therein; 4) a fourth container with a fourth TET2 Product contained therein; 5) a fifth container with a fifth TET2 Product contained therein; 6) optionally a sixth or more additional containers with a sixth or more TET2 Product contained therein; and 7) optionally an additional container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the all of the containers of TET2 Products are different TET2 Products.
  • all of the containers of TET2 Products are the same TET2 Products. In certain embodiments, there can be any combination of same or different TET2 Products in the five or more containers based on the availability of detectable TET2s in a patient's tumor sample(s), the need and/or desire to have multiple TET2 Products for the patient, and the availability of any one TET2 Product that may require or benefit from one or more container.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; and 3) a third container with a third TET2 Product contained therein.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; 3) a third container with a third TET2 Product contained therein; and 4) optionally a fourth container with a fourth TET2 Product contained therein.
  • the article of manufacture may comprise: 1) a first container with a TET2 Product contained therein; 2) a second container with a second TET2 Product contained therein; 3) a third container with a third TET2 Product contained therein; 4) a fourth container with a fourth TET2 Product contained therein; and 5) optionally a fifth container with a fourth TET2 Product contained therein.
  • the article of manufacture may comprise a container with one TET2 Product contained therein.
  • the article of manufacture may comprise a container with two TET2 Products contained therein.
  • the article of manufacture may comprise a container with three TET2 Products contained therein.
  • the article of manufacture may comprise a container with four TET2 Products contained therein.
  • the article of manufacture may comprise a container with five TET2 Products contained therein.
  • the article of manufacture may comprise 1) a first container with one TET2 Product contained therein, and 2) a second container with two TET2 Products contained therein.
  • the article of manufacture may comprise 1) a first container with two TET2 Products contained therein, and 2) a second container with one TET2 Product contained therein.
  • a third and/or fourth container comprising one or more additional TET2 Products may be included in the article of manufacture.
  • a fifth container comprising one or more additional TET2 Products may be included in the article of manufacture.
  • any container of TET2 Product described herein can be split into two, three, or four separate containers for multiple time points of administration and/or based on the appropriate dose for the patient.
  • the TET2 Products are provided in a kit.
  • the kit can, by means of non-limiting examples, contain package insert(s), labels, instructions for using the TET2 Product(s), syringes, disposal instructions, administration instructions, tubing, needles, and anything else a clinician would need in order to properly administer the TET2 Product(s).
  • plasmid DNA-mediated precision genome engineering process for Good Manufacturing Practice (GMP) manufacturing of TET2 Product was developed.
  • Targeted integration of the patient-specific neoTCR was accomplished by electroporating CRISPR endonuclease ribonucleoproteins (RNPs) together with the personalized neoTCR gene cassette, encoded by the plasmid DNA.
  • the TET2 knockout was accomplished by electroporating CRISPR endonuclease ribonucleoproteins (RNPs) that target the TET2 locus.
  • the TET2 Product can be formulated into a drug product using the clinical manufacturing process. Under this process, the TET2 Product is cryopreserved in CryoMACS Freezing Bags. One or more bags may be shipped to the site for each patient depending on patient needs.
  • the product is composed of apheresis-derived, patient-autologous, CD8 and CD4 T cells that have been precision genome engineered to express one or more autologous neoTCRs targeting a neoepitope complexed to one of the endogenous HLA receptors presented exclusively on the surface of that patient's tumor cells.
  • the final product will contain 5% dimethyl sulfoxide (DMSO), human serum albumin, and Plasma-Lyte.
  • DMSO dimethyl sulfoxide
  • human serum albumin human serum albumin
  • Plasma-Lyte Plasma-Lyte
  • TABLE 1 Composition of the TET2 Product Component Specification/Grade Total nucleated NeoTCR cells cGMP manufactured Plasma-Lyte A USP Human Serum Albumin in 0.02-0.08M USP sodium caprylate and sodium tryptophanate CryoStor CS10 cGMP manufactured with USP grade materials
  • compositions comprising cells (e.g., immunoresponsive cells) disclosed herein.
  • the presently disclosed subject matter provides nucleic acid compositions comprising a polynucleotide encoding the NeoTCR disclosed herein.
  • the nucleic acid compositions disclosed herein comprise a polynucleotide encoding a nuclease for the gene disruption of a TET2 locus.
  • the nucleic acid compositions disclosed herein comprise a Cas nuclease and a gRNA for the gene disruption of a TET2 locus.
  • the gRNA has a sequence comprising the nucleotide sequence set forth in SEQ ID NOs: 1-5. Also provided are cells comprising such nucleic acid compositions.
  • the nucleic acid composition further comprises a promoter that is operably linked to the nuclease for the gene disruption of a TET2 locus.
  • the promoter is endogenous or exogenous.
  • the exogenous promoter is selected from the group consisting of an elongation factor (EF)-1 promoter, a CMV promoter, a SV40 promoter, a PGK promoter, a long terminal repeat (LTR) promoter and a metallothionein promoter.
  • the promoter is an inducible promoter.
  • the inducible promoter is selected from the group consisting of a NFAT transcriptional response element (TRE) promoter, a CD69 promoter, a CD25 promoter, an IL-2 promoter, an IL-12 promoter, a p40 promoter, and a Bcl-xL promoter.
  • TRE NFAT transcriptional response element
  • compositions and nucleic acid compositions can be administered to subjects or and/delivered into cells by art-known methods or as described herein.
  • Genetic modification of a cell e.g., a T cell
  • a retroviral vector is employed for the introduction of the DNA construct into the cell.
  • a polynucleotide encoding a nuclease for the gene disruption of a TET2 locus can be cloned into a viral vector and expression can be driven from its endogenous promoter, or from a promoter specific for a target cell type of interest.
  • Non-viral vectors may be used as well.
  • Possible methods of transduction also include direct co-culture of the cells with producer cells, e.g., by the method of Bregni, et al. (1992) Blood 80:1418-1422, or culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and polycations, e.g., by the method of Xu, et al. (1994) Exp. Hemat. 22:223-230; and Hughes, et al. (1992) J. Clin. Invest. 89:1817.
  • transducing viral vectors can be used to modify a cell.
  • the chosen vector exhibits high efficiency of infection and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430, 1997; Kido et al., Current Eye Research 15:833-844, 1996; Bloomer et al., Journal of Virology 71:6641-6649, 1997; Naldini et al., Science 272:263-267, 1996; and Miyoshi et al., Proc. Natl. Acad. Sci. U.S.A. 94:10319, 1997).
  • viral vectors that can be used include, for example, adenoviral, lentiviral, and adena-associated viral vectors, vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, Human Gene Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis et al., BioTechniques 6:608-614, 1988; Tolstoshev et al., Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 17:407-416, 1991; Miller et al., Biotechnology 7:980-990, 1989; LeGal La Salle et al., Science 259:988
  • Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Pat. No. 5,399,346).
  • Non-viral approaches can also be employed for genetic modification of a cell.
  • a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., Proc. Natl. Acad. Sci. U.S.A. 84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990; Brigham et al., Am. J. Med. Sci.
  • Transplantation of normal genes into the affected tissues of a subject can also be accomplished by transferring a normal nucleic acid into a cultivatable cell type ex vivo (e.g., an autologous or heterologous primary cell or progeny thereof), after which the cell (or its descendants) are injected into a targeted tissue or are injected systemically.
  • a cultivatable cell type ex vivo e.g., an autologous or heterologous primary cell or progeny thereof
  • Polynucleotide therapy methods can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element or intron (e.g. the elongation factor 1a enhancer/promoter/intron structure).
  • CMV human cytomegalovirus
  • SV40 simian virus 40
  • metallothionein promoters regulated by any appropriate mammalian regulatory element or intron (e.g. the elongation factor 1a enhancer/promoter/intron structure).
  • enhancers known to preferentially direct gene expression in specific cell types can be used to direct the expression of a nucleic acid.
  • the enhancers used can include, without limitation, those that are characterized as tissue- or cell-specific enhancers.
  • regulation can be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.
  • the resulting cells can be grown under conditions similar to those for unmodified cells, whereby the modified cells can be expanded and used for a variety of purposes.
  • kits for inducing and/or enhancing an immune response and/or treating and/or preventing a cancer or a pathogen infection in a subject comprises an effective amount of presently disclosed cells or a pharmaceutical composition comprising thereof.
  • the kit comprises a sterile container; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art.
  • Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
  • the cells and/or nucleic acid molecules are provided together with instructions for administering the cells or nucleic acid molecules to a subject having or at risk of developing a cancer or pathogen or immune disorder.
  • the instructions generally include information about the use of the composition for the treatment and/or prevention of a neoplasm or a pathogen infection.
  • the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of a cancer, pathogen infection, or immune disorder or symptoms thereof; precautions; warnings; indications; counter-indications; over-dosage information; adverse reactions; animal pharmacology; clinical studies; and/or references.
  • the instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
  • the resulting cells can be grown under conditions similar to those for unmodified cells, whereby the modified cells can be expanded and used for a variety of purposes.
  • the presently disclosed subject matter provides for a cell, comprising an exogenous T cell receptor (TCR), and a gene disruption of a TET2 locus.
  • TCR exogenous T cell receptor
  • A1 The foregoing cell of A, wherein the gene disruption comprises a substitution, a deletion, an insertion, or any combination thereof.
  • A2 The foregoing cell of A or A1, wherein the gene disruption comprises a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof.
  • A5 The foregoing cell of A-A4, comprising a gRNA and a Cas9 nuclease.
  • A6 The foregoing cell of A5, wherein the gRNA comprises a nucleotide sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • A7 The foregoing cell of A-A6, wherein the gene disruption of the TET2 locus enhances cell persistence.
  • A8 The foregoing cell of A-A7, wherein the gene disruption of the TET2 locus enhances memory cell differentiation.
  • A9 The foregoing cell of A-A8, wherein the cell is a primary cell.
  • A10 The foregoing cell of A-A9, wherein the cell is a patient-derived cell.
  • A11 The foregoing cell of A-A10, wherein the cell is a lymphocyte.
  • A12 The foregoing cell of A-A11, wherein the cell is a T cell.
  • A13 The foregoing cell of A12, wherein the cell is CD45RA+, CD62L+, CD28+, CD95-, CCR7+, and CD27+.
  • A14 The foregoing cell of A12, wherein the cell is CD45RA+, CD62L+, CD28+, CD95+, CD27+, CCR7+.
  • A15 The foregoing cell of A12, wherein the cell is CD45RO+, CD62L+, CD28+, CD95+, CCR7+, CD27+, CD127+.
  • A16 The foregoing cell of A-A15, wherein the exogenous TCR is a patient-derived TCR.
  • A17 The foregoing cell of A-A16, wherein the exogenous TCR comprises a signal sequence, a first and second 2A sequence, and a TCR polypeptide sequence.
  • A18 The foregoing cell of A-A17, wherein the exogenous TCR recognizes a cancer antigen.
  • A19 The foregoing cell of A18, wherein the cancer antigen is a neoantigen.
  • A20 The foregoing cell of A18, wherein the cancer antigen is a patient specific antigen.
  • the presently disclosed subject matter provides for a cell modified by a process, the process comprising introducing into a cell a homologous recombination (HR) template nucleic acid sequence; recombining the HR template nucleic acid into an endogenous locus of the cell; and disrupting a TET2 locus of the cell.
  • HR homologous recombination
  • the HR template comprises first and second homology arms homologous to first and second target nucleic acid sequences; and a TCR gene sequence positioned between the first and second homology arms.
  • B6 The foregoing cell of B1-B5, wherein the first and second homology arms are each from about 300 bases to about 2,000 bases in length.
  • the HR template comprises a first signal sequence positioned between the first 2A-coding sequence and the first TCR gene sequence; and a second signal sequence positioned between the second 2A-coding sequence and the second TCR gene sequence; wherein the first and the second signal sequences encode for the same amino acid sequence and are codon diverged relative to each other.
  • B11 The foregoing cell of B8 or B10, wherein the signal sequence is a human growth hormone signal sequence.
  • B16 The foregoing cell of B-B15, wherein the recombining comprises cleavage of the endogenous locus by a nuclease; and recombination of the HR template nucleic acid sequence into the endogenous locus by homology directed repair.
  • B17 The foregoing cell of B16, wherein the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • B18 The foregoing cell of B17, further comprising a gRNA.
  • B19 The foregoing cell of B-B18, wherein the disrupting comprises introducing a substitution, a deletion, an insertion, or any combination thereof.
  • B20 The foregoing cell of B-B19, wherein the disrupting comprises introducing a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof.
  • B21 The foregoing cell of B-B20, wherein the disrupting results in a non-functional TET2 protein.
  • B22 The foregoing cell of B-B21, wherein the disrupting results in knockout of the TET2 gene expression.
  • B23 The foregoing cell of B-B22, wherein the disrupting comprises cleavage of the TET2 locus by a nuclease.
  • B24 The foregoing cell of B23, wherein the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • B25 The foregoing cell of B24, further comprising a gRNA.
  • B26 The foregoing cell of B25, wherein the gRNA comprises a sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • B27 The foregoing cell of B23-B26, wherein the nuclease is expressed by a vector.
  • B28 The foregoing cell of B25-B27, wherein the gRNA is expressed by a vector.
  • B29 The foregoing cell of B27 or B28, wherein the vector is a viral vector.
  • B30 The foregoing cell of B27 or B28, wherein the vector is a non-viral vector.
  • B31 The foregoing cell of B-B30, wherein the disrupting of the TET2 locus enhances cell persistence.
  • B32 The foregoing cell of B-B31, wherein the disrupting of the TET2 locus enhances memory cell differentiation.
  • B33 The foregoing cell of B-B32, wherein the cell is a primary cell.
  • B34 The foregoing cell of B-B33, wherein the cell is a patient-derived cell.
  • B35 The foregoing cell of B-B34, wherein the cell is a lymphocyte.
  • B36 The foregoing cell of B-B35, wherein the cell is a T cell.
  • B37 The foregoing cell of B36, wherein the T cell is a patient-derived cell.
  • B38 The foregoing cell of B-B37, wherein the cell is a young T cell.
  • B39 The foregoing cell of B38, wherein the cell is CD45RA+, CD62L+, CD28+, CD95 ⁇ , CCR7+, and CD27+.
  • B40 The foregoing cell of B38, wherein the cell is CD45RA+, CD62L+, CD28+, CD95+, CD27+, CCR7+.
  • B41 The foregoing cell of B38, wherein the cell is CD45RO+, CD62L+, CD28+, CD95+, CCR7+, CD27+, CD127+.
  • B42 The foregoing cell of B-B41, wherein the endogenous locus is within an endogenous TCR gene.
  • B43 The foregoing cell of B1-B42, wherein the TCR gene sequence encodes for a TCR that recognizes a tumor antigen.
  • B44 The foregoing cell of B43, wherein the tumor antigen is a neoantigen.
  • B45 The foregoing cell of B43, wherein the tumor antigen is a patient specific neoantigen.
  • B46 The foregoing cell of B1-B45, wherein the TCR gene sequence is a patient specific TCR gene sequence.
  • B47 The foregoing cell of B-B46, wherein the process further comprises culturing the cell.
  • B48 The foregoing cell of B47, wherein the culturing is conducted in the presence of at least one cytokine.
  • B49 The foregoing cell of B47 or B48, wherein the culturing is conducted in the presence of IL2, IL7, IL15, or any combination thereof.
  • B50 The foregoing cell of B47 or B48, wherein the culturing is conducted in the presence of IL7 and IL15.
  • the presently disclosed subject matter provides for a method of modifying a cell, the method comprising: introducing into a cell a homologous recombination (HR) template nucleic acid sequence; recombining the HR template nucleic acid into an endogenous locus of the cell; and disrupting a TET2 locus of the cell.
  • HR homologous recombination
  • the HR template comprises: first and second homology arms homologous to first and second target nucleic acid sequences; and a TCR gene sequence positioned between the first and second homology arms.
  • the HR template comprises: a first signal sequence positioned between the first 2A-coding sequence and the first TCR gene sequence; and a second signal sequence positioned between the second 2A-coding sequence and the second TCR gene sequence; wherein the first and the second signal sequences encode for the same amino acid sequence and are codon diverged relative to each other.
  • C16 The foregoing method of C-C15, wherein the recombining comprises cleavage of the endogenous locus by a nuclease; and recombination of the HR template nucleic acid sequence into the endogenous locus by homology directed repair.
  • C17 The foregoing method of C16, wherein the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • C20 The foregoing method of C-C19, wherein the disrupting comprises introducing a missense mutation, a nonsense mutation, a non-frameshift deletion, a frameshift deletion, a non-frameshift insertion, a frameshift insertion, or any combination thereof.
  • C24 The foregoing method of C23, wherein the nuclease is a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) family nuclease, or derivative thereof.
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • C26 The foregoing method of C25, wherein the gRNA comprises a sequence set forth in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, or SEQ ID NO.5.
  • the presently disclosed subject matter provides for a method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of a cell of any one of A-A20 or B-B50.
  • D1 The foregoing method of D, wherein prior to administering the therapeutically effective amount of cells, a non-myeloablative lymphodepletion regimen is administered to the subject.
  • D4 The foregoing method of D2, wherein the solid tumor is selected from the group consisting of melanoma, thoracic cancer, lung cancer, ovarian cancer, breast cancer, pancreatic cancer, head and neck cancer, prostate cancer, gynecological cancer, central nervous system cancer, cutaneous cancer, HPV+ cancer, esophageal cancer, thyroid cancer, gastric cancer, hepatocellular cancer, cholangiocarcinomas, renal cell cancers, testicular cancer, sarcomas, and colorectal cancer.
  • the solid tumor is selected from the group consisting of melanoma, thoracic cancer, lung cancer, ovarian cancer, breast cancer, pancreatic cancer, head and neck cancer, prostate cancer, gynecological cancer, central nervous system cancer, cutaneous cancer, HPV+ cancer, esophageal cancer, thyroid cancer, gastric cancer, hepatocellular cancer, cholangiocarcinomas, renal cell cancers, testicular cancer, sarcomas
  • D5. The foregoing method of D3, wherein the liquid tumor is selected from the group consisting of follicular lymphoma, leukemia, and multiple myeloma.
  • the presently disclosed subject matter provides for a composition comprising an effective amount of a cell of any one of A-A20 or B-B50.
  • composition of E wherein the composition is a pharmaceutical composition that further comprises a pharmaceutically acceptable excipient.
  • E5 The foregoing composition of E-E4, wherein the composition comprises Plasma-Lyte A, HSA, and CryoStor CS10.
  • kits comprising the cell of any one of A-A20 or B-B50, reagents for performing the method of any one of C-C50, or a composition of any one of E-E5.
  • kit further comprises written instructions for treating a cancer.
  • a TET2 Product which is composed of apheresis-derived, patient-autologous, CD8 and CD4 T cells that have been precision genome engineered to express an autologous T cell receptor targeting a neoepitope presented exclusively on the surface of the patient's tumor cells (neoTCR), wherein the TET2 Product comprises T cells with a young phenotype.
  • Neoepitope-specific TCRs identified by the imPACT Isolation Technology described in PCT/US2020/17887 were used to generate homologous recombination (HR) DNA templates. These HR templates were transfected into primary human T cells in tandem with site-specific nucleases (see FIGS. 2A-2C , and FIG. 3 ). The single-step non-viral precision genome engineering resulted in the seamless replacement of the endogenous TCR with the patient's neoepitope-specific TCR, expressed by the endogenous promoter. The TCR expressed on the surface is entirely native in sequence.
  • TLA Targeted Locus Amplification
  • constructs containing genes of interest were inserted into endogenous loci. This was accomplished with the use of homologous repair templates containing the coding sequence of the gene of interest flanked by left and right HR arms. In addition to the HR arms, the gene of interest was sandwiched between 2A peptides, a protease cleavage site that is upstream of the 2A peptide to remove the 2A peptide from the upstream translated gene of interest, and signal sequences ( FIG. 2B ). Once integrated into the genome, the gene of interested expression gene cassette was transcribed as single messenger RNA.
  • flanking regions were unlinked from the gene of interest by the self-cleaving 2A peptide and the protease cleavage site was cleaved for the removal of the 2A peptide upstream from the translated gene of interest ( FIG. 2C ).
  • a gly-ser-gly (GSG) linker was inserted before each 2A peptide to further enhance the separation of the gene of interest from the other elements in the expression cassette.
  • NeoTCRs were integrated into the TCR ⁇ locus of T cells. Specifically, a homologous repair template containing a NeoTCR coding sequence flanked by left and right HR Arms was used. In addition, the endogenous TCR ⁇ locus was disrupted leading to the expression of only TCR sequences encoded by the NeoTCR construct.
  • the general strategy was applied using circular HR templates as well as with linear templates.
  • the neoantigen-specific TCR construct design is diagrammed in FIGS. 3A and 3B .
  • the target TCR ⁇ locus (Ca) is shown along with the plasmid HR template, and the resulting edited sequence and downstream mRNA/protein products are shown.
  • the target TCR ⁇ locus (endogenous TRAC) and its CRISPR Cas9 target site (horizontal stripe, cleavage site designated by arrow) are shown ( FIG. 3A ).
  • NeoTCR cassette The region of the TRAC introduced by the HR template that was codon optimized is shown (vertical stripe).
  • the TCR ⁇ constant domain was derived from TRBC2, which is indicated as being functionally equivalent to TRBC1.
  • the HR template of the NeoTCR expression gene cassette includes two flanking homology arms to direct insertion into the TCR ⁇ genomic locus targeted by the CRISPR Cas9 nuclease RNP with the TCR ⁇ guide RNA. These homology arms (LHA and RHA) flank the neoE-specific TCR sequences of the NeoTCR expression gene cassette. While the protease cleavage site used in this example was a furin protease cleavage site, any appropriate protease cleavage site known to one of skill in the art could be used. Similarly, while HGH was the signal sequence chosen for this example, any signal sequence known to one of skill in the art could be selected based on the desired trafficking and used.
  • the NeoTCR expression gene cassette is transcribed as a single messenger RNA from the endogenous TCR ⁇ promoter, which still includes a portion of the endogenous TCR ⁇ polypeptide from that individual T cell ( FIG. 2C ).
  • the NeoTCR sequences are unlinked from the endogenous, CRISPR-disrupted TCR ⁇ polypeptide by self-cleavage at a P2A peptide ( FIG. 2C ).
  • NeoTCR ⁇ and NeoTCR ⁇ polypeptides are also unlinked from each other through cleavage by the endogenous cellular human furin protease and a second self-cleaving P2A sequence motifs included in the NeoTCR expression gene cassette ( FIG. 2C ).
  • the NeoTCR ⁇ and NeoTCR ⁇ polypeptides are separately targeted by signal leader sequences (derived from the human growth hormone, HGH) to the endoplasmic reticulum for multimer assembly and trafficking of the NeoTCR protein complexes to the T cell surface.
  • signal leader sequences derived from the human growth hormone, HGH
  • HGH human growth hormone
  • the inclusion of the furin protease cleavage site facilitates the removal of the 2A sequence from the upstream TCR ⁇ chain to reduce potential interference with TCR ⁇ function.
  • Inclusion of a gly-ser-gly linker before each 2A (not shown) further enhances the separation of the three polypeptides.
  • TRAC exon 1 vertical stripe
  • NeoTCR Products In addition to NeoTCR Products, this method can be used for any TET2 Product.
  • FIG. 3 shows the results of an In-Out PCR confirming precise target integration of the NeoE TCR cassette.
  • Agarose gels show the results of a PCR using primers specific to the integration cassette and site generate products of the expected size only for cells treated with both nuclease and DNA template (KOKI and KOKIKO), demonstrating site-specific and precise integration.
  • TLA Targeted Locus Amplification
  • Antibody staining for endogenous TCR and peptide-HLA staining for neoTCR reveals that the engineering results in high frequency knock-in of the NeoTCR, with some TCR-cells and few WT T cells remaining ( FIG. 4A ). Knock-in is evidenced by neoTCR expression in the absence of an exogenous promoter. Engineering was carried out multiple times using the same neoTCR with similar results ( FIG. 4B ). Therefore, efficient and consistent expression of the NeoTCR and knockout of the endogenous TCR in engineered T cells was achieved.
  • T cells were transfected with gRNAs targeting the first exon of TET2 as Cas9 RNPs along with the TRA and TRB gRNA-Cas9 RNPs as described in Example 1 and in PCT/US2020/17887 (which is herein incorporated by reference in its entirety), resulting in disruption of the endogenous TET2 coding sequence and reduced TET2 protein expression (i.e., a TET2 Product).
  • TET2 Products were made by first isolating CD4 and CD8 T cells from leukopaks of donors and then transfecting the cells with the TCR ⁇ and TCR ⁇ gRNAs (using the NeoTCR integration methods disclosed in Example 1) along with a TET2 gRNA to knockout the TET2 gene. While any gRNA that specifically binds to TET2, disrupts the TET2 gene, and knocks out the TET2 gene expression can be used, the exemplary gRNAs provided in Table 2 were used herein. sgRNA 1 and 5 are negative strand sgRNAs and sgRNAs 2-4 are positive strand sgRNAs.
  • TET2 gRNA-Cas9 RNP edited CD4 and CD8 T cells described above were lysed and DNA was extracted. Regions flanking the gRNA target sites were amplified via PCR using the exemplary primers provided in Table 3. Alternatively, redesigned primers with more specificity or alternate primers designed to accomplish the amplification could also be used. PCR amplicons were then incubated with T7 endonuclease I (NEB) and resulting products were run on agarose gels ( FIGS. 6A and 6B ).
  • the TET2_1 Fwd primer (SEQ ID NO:6) was used for analyzing sgRNA indels for sgRNA 1 (SEQ ID NO:1), 4 (SEQ ID NO:4), and 5 (SEQ ID NO:5).
  • the expected product size for this reaction is 849 bp.
  • the TET2_1 Rev primer (SEQ ID NO:7) was used for analyzing sgRNA indels for sgRNA 1 (SEQ ID NO:1), 4 (SEQ ID NO:4), and 5 (SEQ ID NO:5).
  • the expected product size for this reaction is 849 bp.
  • the TET2_2 Fwd primer (SEQ ID NO: 8) was used for analyzing sgRNA indels for sgRNA 2 (SEQ ID NO:2) and 3 (SEQ ID NO:3).
  • the expected product size for this reaction is 1032 bp.
  • the TET2_2 Rev primer (SEQ ID NO:9) was used for analyzing sgRNA indels for sgRNA (SEQ ID NO:2) and 3 (SEQ ID NO:3).
  • the expected product size for this reaction is 1032 bp.
  • the optimal gRNA was determined by assessing the TET2 knock out (KO) via a T7 endonuclease I (T7EI) assay to detect non-perfectly annealed PCR products. Further characterization of loss of gene expression was determined by qPCR quantification of TET2 mRNA and Western blot for TET2 protein in neoTCR T cells nucleofected with TET2 gRNA. T cells untreated with TET2 gRNA were used as a negative control for TET2 gene and protein expression. The T7EI assay quantified the gRNA targeting efficiency by measuring the fraction of the PCR product that was cleaved by the T7EI enzyme. TET2 mRNA transcript abundance was determined by qPCR. TET2 protein abundance was determined via Western blot using an anti-TET2 antibody. Successful knock out of the TET2 gene resulted in reduced mRNA and protein levels in the TET2 Products compared to that of the NeoTCR Products.
  • T7EI T
  • crispr-dav https://github.com/pinetreel/crispr-dav/blob/master/Install-and-Run.md#description-of-files-created-by-prepare runpl-script) analysis was performed to identify the most efficient gRNA for generating outframe indels. Coverage of the PCR amplicons was robust for all amplicons surrounding the guide site. See, FIGS. 7A-7E .
  • RNAs Five distinct guide RNAs were designed to target the first coding exon of TET2 and robustly edit and lead to >70% out of frame indels as assessed by the T7E1 cutting efficiency assay as well as PCR amplicon DNA transposon-based sequencing ( FIGS. 8A and 8B ).
  • 5-hmC Flow Cytometry experiment was performed as follows: 1) 200K T cells from WT and each gRNA nucleofected sample were stimulated for 1.5h on a plate coated PACT035 comPACT, 2) samples were then harvest and stained for Live/Dead and then fixed with BD ICS Fix/Perm followed by 2 washes and resuspension in Staining Buffer, 3) the cells were permeabilized for 15 min in Perm Buffer, 4) the cells were treated with DNaseI (300 ug/mL) in Perm Buffer for 3 hr at 37 C (wanted to treat for 1 hr), 5) the cells were washed 2 ⁇ with Perm Buffer, 6) the cells were stained with anti-5-hmC (1 ug/mL)
  • ATAC-seq (as described in Buenrostro et al., 2013, N. Methods, 10(12) 1213-1218) was performed on the TET2 Products to determine the genome-wide chromatin state of the cells.
  • TCF7 and TBET staining of the resting TET2 Products was also performed ( FIG. 10 ). It was shown that knocking out TET2 had no effect on the expression of the TCF7 and TBET transcription factors.
  • TET2 Products The ability of TET2 Products to produce IFN ⁇ was tested ( FIG. 11A ). It was determined that knocking out TET2 reduced the frequency of IFN ⁇ producing T cells compared to NeoTCR Products.
  • TET2 Products were tested to determine if the number of CD107a+ cells would be affected by the knockout ( FIG. 11B ). It was determined that knocking out TET2 reduced the frequency of CD107a+ T cells compared to NeoTCR Products.
  • FIGS. 12A and 12B Multiple rounds of IncuCyte experiments were performed using TET2 Products (the “PACT-035-TCR089” cells) and NeoTCR Products (the “PACT035-TCR089 TET2 gRNA3” cells) ( FIGS. 12A and 12B ).
  • TET2 Products the “PACT-035-TCR089” cells
  • NeoTCR Products the “PACT035-TCR089 TET2 gRNA3” cells
  • TET2 disruption enhances CD8 memory cell differentiation (Carty et al., 2018; Fraietta et al., 2018, Nature, 558(7709), 307-312).
  • the phenotypic state of the edited cells was assessed via flow cytometry after staining with antibodies against CCR7 and CD27. Based on these experiments, it was shown that TET2 Products are enriched for expression of CCR7 and CD27 as compared to control T cells and NeoTCR Products indicating that TET2 Products comprise Tcm T cells.
  • CD27 is a member of the TNF receptor family. It is also constitutively expressed on central memory T (Tcm) and naive T cells (Tn). To determine if the TET2 Product cells had a memory-like phenotype, the TET2 Product cells were stimulated for 7 days via cognate comPACT coating. This stimulation revealed an increased frequency of cells expressing CD27 ( FIG. 14B ) and CCR7 ( FIG. 14A ) among TET2 Product cells. In other words, the TET2 Product cells were shown to have a memory-like phenotype.
  • TET2 Products were performed on the TET2 Products. Specifically, intracellular staining and detection via flow cytometry and neoantigen-specific killing assays were performed. The results of these experiments showed that TET2 Products produce higher levels of effector cytokines and release more cytotoxic granules than cells that express TET2 (e.g., NeoTCR Products).
  • T cells were transfected with gRNAs targeting the first exon of TET2 as Cas9 RNPs along with the TRA and TRB gRNA-Cas9 RNPs as described in Example 1 and in PCT/US2020/17887 (which is herein incorporated by reference in its entirety), resulting in disruption of the endogenous TET2 coding sequence and reduced TET2 protein expression.
  • CD4 and CD8 T cells were isolated from healthy donor PBMCs. By means of example, isolation of such cells can be achieved using the Miltenyi Prodigy or Miltenyi MACS separation columns according to the manufacturers' instructions. Positively-selected CD4 and CD8 T cells (for example, using Miltenyi antibodies and isolation column) were used fresh or cryopreserved in 1% human serum albumin, 49% plasmalyte (Baxter), and 50% CS10 (Sigma).
  • Cryopreserved cells were thawed, washed in TexMACS (Miltenyi)+10% human AB serum (Valley Biomedical), and seeded at a density of 2 ⁇ 106 cells per mL in TexMACS+3% human AB serum (culture medium).
  • TexMACS Miltenyi
  • human AB serum vanadium AB serum
  • One day after thawing, or immediately if used fresh the cells were washed and re-seeded at a density of 1.46 ⁇ 106 cells per mL in culture medium+12.5 ng/mL IL7+12.5 ng/mL IL15+1:17.5 ratio of TransACT T cell activation reagent (all reagents from Miltenyi) by volume.
  • T cells were electroporated with a plasmid comprising the NeoTCR of interest.
  • Neoantigen-specific peptide-HLA complex polypeptides i.e., each a “comPACT”
  • a comPACT-dextramer complex was made for the labeling of neoTCR expressing T cells.
  • Biotinylated comPACT protein was incubated with a streptavidin-conjugated fluorophore for 10 min at room temperature (RT).
  • Biotin-40-dextran (NANOCS) was added to the mixture and incubated at RT for an additional 10 minutes.
  • the comPACT-Dextramers were stored at 4° C.
  • T cells were stained for flow cytometry on the indicated days. Cells were first stained with viability dye for 20 minutes at 4° C., then washed and stained with the comPACT-dextramer for 10 minutes at 4° C. Surface antibodies (anti-CD8 ⁇ , anti-CD8 ⁇ , anti-CD4) were added to the suspension of cells and comPACT-dextramer, and the cells were incubated for an additional 20 minutes at 4° C. Cells were then washed and fixed in intracellular fixation buffer (BD Biosciences). All cells were acquired on an Attune NxT Flow Cytometer (ThermoFisher Scientific) and data was analyzed with either FCS Express or FlowJo.
  • Cytometric Bead Array Streptavidin coated plates (Eagle Biosciences) were washed 3 times with wash buffer (PBS supplemented with 1% BSA and 0.05% tween20) and then coated with comPACTs at different concentrations ranging from 100-0.01 ng/well. Wells with no comPACTs and wells coated with mismatched comPACTs as used as controls. The plates were incubated for 2 hr at room temperature, washed three times with wash buffer, and then washed three times with TexMACS supplemented with 3% human AB serum to remove the tween20.
  • wash buffer PBS supplemented with 1% BSA and 0.05% tween20
  • T cells were given two washes with TexMACS supplemented with 3% human AB serum and resuspended at 1 million cells/mL in TexMACS supplemented with 3% human AB serum and 1 ⁇ penicillin-streptomycin solution.
  • T cells were plated onto the comPACT coated plate at 100 ⁇ L/well and incubated at 37° C., 5% CO2. After 24h the supernatant was collected, and the cytokine concentrations were analyzed using the BD Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit II (Catalog No. 551809) following the manufacturer's protocol.
  • CBA Cytometric Bead Array
  • Capture beads were mixed with culture supernatant, incubated with the detection reagent for 3 hr at RT protected from light, washed, and resuspended in wash buffer. Samples were assayed on an Attune NxT Flow Cytometer and data analyzed with FlowJo.
  • the EC50 represents the concentration of cognate comPACT that elicits 50% of the maximum response and was calculated utilizing a least-squares fit of IFN ⁇ secretion over a range of comPACT concentrations.
  • T cells were stained for flow cytometry on the indicated days. T cells were first stained with viability dye for 20 minutes at 4° C., then washed and incubated with surface antibodies (anti-CD8 ⁇ , anti-CD8 ⁇ , anti-CD4) for an additional 20 minutes at 4° C. T cells were then washed and permeabilized for intracellular staining. T cells were stained with anti-2A peptide or with anti-IFN ⁇ , anti-TNF, or anti-IL2 in permeabilization buffer for 20 minutes at 4° C. T cells were fixed in intracellular fixation buffer (BD Biosciences). Samples were assayed on an Attune NxT Flow Cytometer (ThermoFisher Scientific) and data analyzed with either FCS Express or FlowJo.
  • T cell Proliferation Assay Edited CD4 and CD8 T cells were labeled with the e450 proliferation dye (eBioscience) according to the manufacturer's instructions. Labeled cells were stimulated on comPACT coated plates with a range of concentrations as described above. T cells were harvested over 48-96 hours and analyzed for proliferation as measured by dilution of the e450 dye.
  • e450 proliferation dye eBioscience
  • HLA-matched cell lines were pulsed with the cognate neoantigen peptide or mismatched peptide for 1h at 37° C., 5% CO2. The cells were washed 3 times with media to remove any unbound peptide and then co-cultured with edited CD4 and CD8 T cells that are labeled with the e450 proliferation dye described above. Co-cultures were incubated for 48h at 37° C. with 5% CO2 before harvest. Cells were washed and stained with a fixable viability dye to determine killing efficiency. The e450 proliferation dye is used to distinguish edited T cells from target cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
US17/099,140 2019-05-01 2020-11-16 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy Abandoned US20210085720A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/099,140 US20210085720A1 (en) 2019-05-01 2020-11-16 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841748P 2019-05-01 2019-05-01
US201962841753P 2019-05-01 2019-05-01
PCT/US2020/030704 WO2020223478A1 (en) 2019-05-01 2020-04-30 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
US17/099,140 US20210085720A1 (en) 2019-05-01 2020-11-16 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/030704 Continuation WO2020223478A1 (en) 2019-05-01 2020-04-30 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy

Publications (1)

Publication Number Publication Date
US20210085720A1 true US20210085720A1 (en) 2021-03-25

Family

ID=73029470

Family Applications (4)

Application Number Title Priority Date Filing Date
US17/099,140 Abandoned US20210085720A1 (en) 2019-05-01 2020-11-16 Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
US17/100,223 Active 2040-07-10 US11304978B2 (en) 2019-05-01 2020-11-20 Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
US17/691,565 Active 2041-01-01 US12247061B2 (en) 2019-05-01 2022-03-10 Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
US19/044,972 Pending US20260001931A1 (en) 2019-05-01 2025-02-04 Compositions and methods for the treatment of cancer using a cd8 engineered t cell therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/100,223 Active 2040-07-10 US11304978B2 (en) 2019-05-01 2020-11-20 Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
US17/691,565 Active 2041-01-01 US12247061B2 (en) 2019-05-01 2022-03-10 Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
US19/044,972 Pending US20260001931A1 (en) 2019-05-01 2025-02-04 Compositions and methods for the treatment of cancer using a cd8 engineered t cell therapy

Country Status (11)

Country Link
US (4) US20210085720A1 (https=)
EP (2) EP3962938A4 (https=)
JP (2) JP7717619B2 (https=)
KR (2) KR20220004703A (https=)
CN (1) CN113748127B (https=)
AU (2) AU2020264484A1 (https=)
CA (2) CA3151385A1 (https=)
IL (2) IL287643A (https=)
MX (2) MX2021013225A (https=)
SG (2) SG11202111865UA (https=)
WO (3) WO2020223478A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064637A3 (en) * 2022-09-19 2024-05-16 Emendobio Inc. Biallelic knockout of faslg
WO2024064606A3 (en) * 2022-09-19 2024-05-16 Emendobio Inc. Biallelic knockout of ctla4
WO2024064607A3 (en) * 2022-09-19 2024-05-30 Emendobio Inc. Biallelic knockout of tet2

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114788A1 (en) * 2018-09-28 2020-04-02 Memorial Sloan-Kettering Cancer Center Immunoresponsive cells expressing dominant negative fas and uses thereof
US12344656B2 (en) * 2019-09-06 2025-07-01 Crispr Therapeutics Ag Genetically engineered T cells having improved persistence in culture
WO2021216993A1 (en) * 2020-04-24 2021-10-28 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
CA3201767A1 (en) * 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
WO2022140361A1 (en) * 2020-12-22 2022-06-30 Ludwig Institute For Cancer Research Ltd Genetically engineered lymphocytes for adoptive cell therapy
US20240108652A1 (en) * 2021-02-18 2024-04-04 University Of Florida Research Foundation, Incorporated Enhancing metabolic fitness of t cells to treat cancer
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
WO2022242644A1 (zh) * 2021-05-18 2022-11-24 赛斯尔擎生物技术（上海）有限公司 修饰细胞的方法
KR20240021216A (ko) * 2021-06-11 2024-02-16 팩트 파마, 인크. 세포 생성물을 감정하는 방법
EP4405464A4 (en) * 2021-09-21 2025-12-03 Univ Chicago METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
KR20240112376A (ko) 2021-10-28 2024-07-18 라이엘 이뮤노파마, 인크. c-Jun을 발현하는 세포를 배양하는 방법
CN114373511B (zh) * 2022-03-15 2022-08-30 南方医科大学南方医院 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法
WO2023212507A1 (en) * 2022-04-26 2023-11-02 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
WO2025027088A1 (en) * 2023-07-31 2025-02-06 T-Knife Gmbh An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
AU2024332117A1 (en) * 2023-08-25 2026-02-12 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US20020127594A1 (en) * 2000-06-22 2002-09-12 Gearing David P. Don-1 gene and polypeptides and uses therefor
US6355412B1 (en) * 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US20160296562A1 (en) * 2013-11-21 2016-10-13 Ucl Business Plc Cell
AU2015342867B2 (en) 2014-11-06 2020-03-26 University Of Maryland, Baltimore CD8alpha and T cell receptor variants and methods of using same in modulating immune cell responses
CN113349159B (zh) 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
JP2018531593A (ja) 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法
US20180258149A1 (en) * 2015-09-17 2018-09-13 Novartis Ag Car t cell therapies with enhanced efficacy
IL297018A (en) * 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Directed cleavage of cell mhc receptor
CN115109120A (zh) * 2016-04-04 2022-09-27 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法
CA3035075A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
MX2019010972A (es) * 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
BR112019019426A2 (pt) 2017-03-22 2020-05-26 Novartis Ag Biomarcadores e terapias com células t car com eficácia intensificada
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
US11512287B2 (en) * 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
US11352389B2 (en) * 2017-06-30 2022-06-07 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) Treatment of haematological malignancies
AU2018329741B2 (en) * 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
MX2020004541A (es) * 2017-10-30 2021-04-12 Pact Pharma Inc Edicion de genes de celulas primarias.
US20200338128A1 (en) * 2018-01-05 2020-10-29 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
SG11202009761YA (en) 2018-04-02 2020-10-29 Pact Pharma Inc Peptide-mhc compacts
CN113166778A (zh) * 2018-09-05 2021-07-23 葛兰素史克知识产权开发有限公司 T细胞修饰
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
IL316576A (en) 2019-02-12 2024-12-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
WO2020243134A1 (en) * 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064637A3 (en) * 2022-09-19 2024-05-16 Emendobio Inc. Biallelic knockout of faslg
WO2024064606A3 (en) * 2022-09-19 2024-05-16 Emendobio Inc. Biallelic knockout of ctla4
WO2024064607A3 (en) * 2022-09-19 2024-05-30 Emendobio Inc. Biallelic knockout of tet2

Also Published As

Publication number Publication date
JP7717619B2 (ja) 2025-08-04
WO2020223478A1 (en) 2020-11-05
CA3151385A1 (en) 2020-11-05
MX2021013225A (es) 2022-01-06
WO2020223625A1 (en) 2020-11-05
US11304978B2 (en) 2022-04-19
US20210085721A1 (en) 2021-03-25
EP3953379A4 (en) 2023-05-31
KR20220005050A (ko) 2022-01-12
CN113748127A (zh) 2021-12-03
EP3962938A1 (en) 2022-03-09
US20260001931A1 (en) 2026-01-01
EP3962938A4 (en) 2023-07-05
JP2022530653A (ja) 2022-06-30
EP3953379A1 (en) 2022-02-16
WO2020223537A8 (en) 2021-11-11
AU2020266579A1 (en) 2021-11-25
SG11202111865UA (en) 2021-11-29
IL287639A (en) 2021-12-01
CA3136740A1 (en) 2020-11-05
JP2022531231A (ja) 2022-07-06
IL287643A (en) 2021-12-01
US12247061B2 (en) 2025-03-11
CN113748127B (zh) 2025-01-10
KR20220004703A (ko) 2022-01-11
MX2021013218A (es) 2021-12-10
AU2020264484A1 (en) 2021-11-04
WO2020223537A1 (en) 2020-11-05
SG11202111532SA (en) 2021-11-29
US20220193139A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
US20210085720A1 (en) Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
Espinosa-Carrasco et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
US11643668B2 (en) CRISPR/Cas9 complex for genomic editing
US20240066063A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY
JP2021518161A6 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
US20220010274A1 (en) Personalized neoantigen-specific adoptive cell therapies
Chuntova et al. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice
Espinosa-Carrasco et al. Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors
Du et al. Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer
US20230355762A1 (en) Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
JP2011520473A (ja) 抗腫瘍細胞
US20210106621A1 (en) Method of treating immunotherapy non-responders with an autologous cell therapy
CN118853582A (zh) 基因编辑的肿瘤浸润淋巴细胞及其在免疫细胞治疗中的应用
HK40065093A (en) Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy
Navarre et al. Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses
WO2025054946A1 (zh) 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2024216073A1 (en) Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: PACT PHARMA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SENNINO, BARBARA;JACOBY, KYLE;MANDL-CASHMAN, STEFANIE;AND OTHERS;SIGNING DATES FROM 20200427 TO 20200828;REEL/FRAME:059081/0909

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

AS Assignment

Owner name: ADOC SSF, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PACT PHARMA, INC.;REEL/FRAME:063927/0840

Effective date: 20230606

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION